John Chia - Clinician/Researcher

I took Equillibrant years ago and so did my friend. We also took inosine and Immunovir. None of these treatments improved my symptoms, inosine did nothing and Immunovir gave me a terrible relapse. My friend felt no difference from the treatments.

My understanding is that Dr. Chia's son recovered from CFS from taking supplements and interferon treatments.

It would be a very convenient backstory to make up your son recovered from ME via your supplements.
 
Oxymatrine alleviates symptoms in high-fat diet and STZ-induced SD in rats with painful diabetic neuropathy by reducing inflammation and oxidative stress

Abstract
Introduction:

Painful Diabetic Neuropathy (PDN) is a severe complication of diabetes, featured by intricate aetiology and multiple side effects of current therapeutic approaches. In recent years, the glymphatic system has attracted increasing attention for its role in PDN. This study investigated the regulatory effects and underlying mechanisms of Oxymatrine (OMT) on the spinal glymphatic system in PDN rat models, aiming to provide novel therapeutic insights for PDN.

Methods:

The PDN rat model was established by high-fat and high-sugar diet combined with streptozotocin (STZ) induction. The 50% paw withdrawal threshold (50% PWT) was measured by Von Frey filaments to evaluate neuropathic pain. Spinal glymphatic system function was observed via Magnetic Resonance Imaging (MRI). Western blotting was used to detect the expression of Aquaporin-4 (AQP-4), Metalloproteinase-9 (MMP-9), NF-κB p65, p-p65, Nrf2 and HO-1. Immunofluorescence was performed to assess AQP4 polarization and nuclear expression of p65. In addition, the levels of oxidative stress indicators (GSH, SOD, MDA) and inflammatory factors (IL-1β, IL-6, TNF-α) were determined.

Results:

OMT treatment significantly alleviated PDN-related symptoms and improved the detected indicators. It effectively reduced oxidative stress and inflammatory levels, upregulated the expression of Nrf2 and HO-1, downregulated MMP-9 expression, repaired AQP-4 polarisation, and restored the function of the spinal glymphatic system in PDN rats.

Discussion:

This study provides a theoretical foundation for the potential application of OMT as a therapeutic agent for PDN, and its multi-target regulatory mechanism offers new directions for PDN treatment.

 
In summary, this study has thoroughly investigated the mechanisms by which OMT ameliorates the function of the glymphatic system by improving the spinal cord OS status and levels of inflammatory factors in PDN rats. The results indicate that OMT significantly enhances the antioxidant capacity in PDN rats and effectively reduces OS levels by activating the Nrf2 pathway. Meanwhile, OMT also reduces the production of inflammatory factors and regulates the expression of MMP-9 by inhibiting the NF-κB pathway.
These changes collectively improve the activation state of astrocytes, restore the polarized localization of AQP4, and enhance the function of the glymphatic system, thereby effectively alleviating PDN symptoms. This finding provides a substantial theoretical basis for the potential application of OMT in PDN treatment.
 
Back
Top Bottom